Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719523 · ClinicalTrials.gov registry record · Phase 1
Open-Trial of EPI-743 for Adults With Tourette Syndrome
A Phase 1 study of Tourette Syndrome, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01719523 is a Phase 1 study of Tourette Syndrome that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01719523, a Phase 1 study of Tourette Syndrome, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of EPI-743 on tic severity in adults with Tourette syndrome.
Conditions Studied
Interventions
- DRUG EPI-743
Study Locations (1)
Connecticut
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01719523
The ClinicalTrials.gov registry entry for NCT01719523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (88% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 1 intervention - of which EPI-743 is the first listed.
NCT01719523 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01719523 about?
NCT01719523 is a clinical study titled "Open-Trial of EPI-743 for Adults With Tourette Syndrome". The purpose of this study is to examine the effects of EPI-743 on tic severity in adults with Tourette syndrome.
What is the current status of trial NCT01719523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-10. Estimated completion is 2013-10.
What conditions does trial NCT01719523 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT01719523?
The interventions under investigation include: EPI-743 (DRUG).
Who is sponsoring clinical trial NCT01719523?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01719523 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing Cognitive Training for Tourette Syndrome
COMPLETED · Phase 1
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.